 Connection
Edward Janoff to Pneumococcal Infections
This is a "connection" page, showing publications Edward Janoff has written about Pneumococcal Infections.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
4.393 |
|
|
|
-
Nicholson LK, Kofonow JM, Robertson CE, Wright T, Li Q, Gardner EM, Frank DN, Janoff EN. Clinical and Microbial Determinants of Upper Respiratory Colonization With Streptococcus pneumoniae and Native Microbiota in People With Human Immunodeficiency Virus Type 1 and Control Adults. J Infect Dis. 2024 Dec 16; 230(6):1456-1465.
Score: 0.833
-
Jha V, Nicholson LK, Gardner EM, Rahkola JT, Pratap H, Scott J, Borgeson M, Jacobelli J, Janoff EN. Impact of HIV-1 Infection and Antigen Class on T Follicular Helper Cell Responses to Pneumococcal Polysaccharide-Protein Conjugate Vaccine-13. J Immunol. 2021 05 15; 206(10):2402-2411.
Score: 0.648
-
Iroh Tam PY, Thielen BK, Obaro SK, Brearley AM, Kaizer AM, Chu H, Janoff EN. Childhood pneumococcal disease in Africa - A systematic review and meta-analysis of incidence, serotype distribution, and antimicrobial susceptibility. Vaccine. 2017 04 04; 35(15):1817-1827.
Score: 0.486
-
Janoff EN, Rubins JB, Fasching C, Charboneau D, Rahkola JT, Plaut AG, Weiser JN. Pneumococcal IgA1 protease subverts specific protection by human IgA1. Mucosal Immunol. 2014 Mar; 7(2):249-56.
Score: 0.377
-
Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis. 2008 Nov 15; 47(10):1328-38.
Score: 0.273
-
Fasching CE, Grossman T, Corthésy B, Plaut AG, Weiser JN, Janoff EN. Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae. Infect Immun. 2007 Apr; 75(4):1801-10.
Score: 0.241
-
Finn A, Zhang Q, Seymour L, Fasching C, Pettitt E, Janoff EN. Induction of functional secretory IgA responses in breast milk, by pneumococcal capsular polysaccharides. J Infect Dis. 2002 Nov 15; 186(10):1422-9.
Score: 0.179
-
Rubins JB, Janoff EN. Pneumococcal disease in the elderly: what is preventing vaccine efficacy? Drugs Aging. 2001; 18(5):305-11.
Score: 0.158
-
Rubins JB, Cheung S, Carson P, Rubins HB, Janoff EN. Identification of clinical risk factors for nosocomial pneumococcal bacteremia. Clin Infect Dis. 1999 Jul; 29(1):178-83.
Score: 0.143
-
Rubins JB, Puri AK, Loch J, Charboneau D, MacDonald R, Opstad N, Janoff EN. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis. 1998 Aug; 178(2):431-40.
Score: 0.134
-
Hibbs JR, Douglas JM, Judson FN, McGill WL, Rietmeijer CA, Janoff EN. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994. Clin Infect Dis. 1997 Aug; 25(2):195-9.
Score: 0.125
-
Janoff EN, Rubins JB. Invasive pneumococcal disease in the immunocompromised host. Microb Drug Resist. 1997; 3(3):215-32.
Score: 0.120
-
Opstad NL, Daley CL, Thurn JR, Rubins JB, Merrifield C, Hopewell PC, Janoff EN. Impact of Streptococcus pneumoniae bacteremia and human immunodeficiency virus type 1 on oral mucosal immunity. J Infect Dis. 1995 Aug; 172(2):566-70.
Score: 0.109
-
Roche AM, Richard AL, Rahkola JT, Janoff EN, Weiser JN. Antibody blocks acquisition of bacterial colonization through agglutination. Mucosal Immunol. 2015 Jan; 8(1):176-85.
Score: 0.101
-
Janoff EN, O'Brien J, Thompson P, Ehret J, Meiklejohn G, Duvall G, Douglas JM. Streptococcus pneumoniae colonization, bacteremia, and immune response among persons with human immunodeficiency virus infection. J Infect Dis. 1993 Jan; 167(1):49-56.
Score: 0.091
-
Janoff EN, Breiman RF, Daley CL, Hopewell PC. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med. 1992 Aug 15; 117(4):314-24.
Score: 0.089
-
Crum-Cianflone NF, Huppler Hullsiek K, Roediger M, Ganesan A, Patel S, Landrum ML, Weintrob A, Agan BK, Medina S, Rahkola J, Hale BR, Janoff EN. A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults. J Infect Dis. 2010 Oct 01; 202(7):1114-25.
Score: 0.078
-
Crum-Cianflone NF, Roediger M, Huppler Hullsiek K, Ganesan A, Landrum M, Weintrob A, Agan B, Medina S, Rahkola J, Hale B, Janoff EN. The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection. Vaccine. 2010 Nov 10; 28(48):7583-8.
Score: 0.078
-
Bliss SJ, O'Brien KL, Janoff EN, Cotton MF, Musoke P, Coovadia H, Levine OS. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis. 2008 Jan; 8(1):67-80.
Score: 0.064
-
French N, Nakiyingi J, Carpenter LM, Lugada E, Watera C, Moi K, Moore M, Antvelink D, Mulder D, Janoff EN, Whitworth J, Gilks CF. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000 Jun 17; 355(9221):2106-11.
Score: 0.038
-
Brichacek B, Swindells S, Janoff EN, Pirruccello S, Stevenson M. Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J Infect Dis. 1996 Dec; 174(6):1191-9.
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|